BI-4020

Overview

BI-4020 is a fourth-generation, orally active, and non-covalent EGFR tyrosine kinase inhibitor. BI-4020 inhibits not only the triple mutant EGFR del19 T790M C797S variant ( IC 50 =0.2 nM in BaF3 cell lines) but also the double mutant EGFR del19 T790M and primary mutant EGFR del19 ( IC 50 =1 nM). BI-4020 also shows activity against EGFR wt ( IC 50 =190 nM). BI-4020 shows high kinome selectivity and good DMPK properties.

Application

Products | Products > Signaling Pathways > JAK/STAT Signaling | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Signaling Pathways > EGFR

Product Information

• Catalog No.: HY-129550
• CAS No.: 2664214-60-0
• Molecular Formula: C30H38N8O2
• Molecular Weight: 542.68
• Purity: 99.30%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
• Solubility: ≥ 2.08 mg/mL (3.83 mM); Clear solution
• Availability: In-stock

Source

Original product source